:
Breast cancer is the most common invasive cancer in women, and the second main cause of
deaths in women, after lung cancer. There is continuous advancement in the development of therapeutic
agents against breast cancer in recent years and it is still in progress. Development of hybrid molecules
by combining different pharmacophores to obtain significant biological activity is an excellent
approach. Coupling of coumarin scaffold with other distinct motifs has led to the design of newer
compounds against breast cancer. These distinct pharmacophores possess a diverse mode of action as
well as selectivity. It has been reported in the literature that coumarin hybrids possess significant
potency against breast cancer by binding to various biological targets which are associated with
breast cancer. Due to low toxicity profile on various organ systems, coumarin hybrids have nowadays
attracted the keen attention of researchers to explore their therapeutic ability against breast
cancer. Reported coumarin hybrids include coupling with isoxazole, thiazole, monastrol, chalcone,
triazole, sulphonamide, triphenylethylene, benzimidazole, pyran, imidazole, stilbene, oestrogen,
phenylsulphonylfuroxan, etc. In the present review, a description of various coumarin hybrid molecules
has been presented along with their structural-activity relationships.
SOX2 Drives Bronchial Dysplasia in a Novel Organotypic Model of Early Human Squamous Lung Cancer
